Deleterious NF1 mutations have been previously reported in non‐small‐cell lung cancer (NSCLC), but the genomic landscape of this molecular subgroup remains poorly characterized in the lung cancer population; the clinical outcomes of NF1 mutant NSCLC also remain unknown. The gene discussed is NF1; the disease is non-small cell lung carcinoma.